Merck to Acquire Terns Pharmaceuticals in $6.7 Billion Deal

<p>Watch Scarlet and Paul LIVE every day on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.<br /><br />Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu<br /><br />-Michelle Davis, Bloomberg News Senior Deals Reporter, discusses Merck agreeing to buy Terns Pharmacueticals for $6.7 billion, giving the company access to a promising new leukemia treatment. The acquisition is expected to close in the second quarter, with Merck paying $53 per share in cash for Terns, a 6% premium to its closing price on Tuesday.<br /><br />-Geetha Ranganathan, Bloomberg Intelligence Analyst on US Media, discusses the latest at Walt Disney and Netflix. Walt Disney Co. Chief Executive Officer Josh D&rsquo;Amaro has seen two billion-dollar technology bets falter, with one of them unraveling entirely, just days into his new job. Separately, Netflix Inc.'s push into livestreaming mega events in Asia is set to accelerate, buoyed by hits from the World Baseball Classic to BTS's comeback show.<br /><br />-Diana Rosero Pena, Bloomberg Intelligence Consumer Staples Analyst, discusses Chewy earnings. Chewy forecast sales for the year that beat analyst estimates, suggesting the online pet retailer expects strong demand to more than make up for headwinds including inflation and tariff uncertainty.<br /><br />-Justin Pridon, VP, Consulting Services at Revenue Management Solutions, discusses restaurant trends from the BI Farm, Food &amp; Fuel Conference. He talks about what restaurant menus reveal about where food demand is headed, why protein is winning, and how demand might change with rising gas prices.</p> <p>&nbsp;</p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>